[French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. From the National Reference and the Competence centers for rare diseases and the Société de Pneumologie de Langue Française].

[1]  B. Corrin.  Classification of the idiopathic interstitial pneumonias. , 2014, American journal of respiratory and critical care medicine.

[2]  A. Wells,et al.  Acute Exacerbations of Idiopathic Pulmonary Fibrosis , 2013, Respiration.

[3]  K. Anstrom,et al.  Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. , 2013, Chest.

[4]  G. Raghu,et al.  Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial , 2013, European Respiratory Journal.

[5]  Charlie Strange,et al.  An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. , 2012, American journal of respiratory and critical care medicine.

[6]  Luba Nalysnyk,et al.  Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature , 2012, European Respiratory Review.

[7]  J. Behr,et al.  Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease , 2012, European Respiratory Journal.

[8]  T. Maher.  Faculty Opinions recommendation of Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. , 2012 .

[9]  A. Wells.  Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow's ear , 2012, Thorax.

[10]  K. Horton,et al.  Thalidomide for the Treatment of Cough in Idiopathic Pulmonary Fibrosis , 2012, Annals of Internal Medicine.

[11]  V. Cottin,et al.  Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis? , 2012, European Respiratory Journal.

[12]  A. Günther,et al.  Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial , 2012, European Respiratory Journal.

[13]  K. Anstrom,et al.  A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. , 2012, American journal of respiratory and critical care medicine.

[14]  L. Spencer,et al.  Ambulatory oxygen in idiopathic pulmonary fibrosis: of what benefit? , 2012, European Respiratory Journal.

[15]  Kevin J Anstrom,et al.  Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. , 2012, The New England journal of medicine.

[16]  Joyce S Lee,et al.  A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis , 2012, Annals of Internal Medicine.

[17]  F. Martinez,et al.  ARTEMIS-IPF: A Placebo-Controlled Trial Of Ambrisentan In Idiopathic Pulmonary Fibrosis , 2012, ATS 2012.

[18]  Joyce S Lee,et al.  Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis , 2012, Thorax.

[19]  A. Holland,et al.  Predictors of benefit following pulmonary rehabilitation for interstitial lung disease. , 2012, Respiratory medicine.

[20]  C. Fell.  Idiopathic pulmonary fibrosis: phenotypes and comorbidities. , 2012, Clinics in chest medicine.

[21]  G. Raghu,et al.  Silent gastro-oesophageal reflux and microaspiration in IPF: mounting evidence for anti-reflux therapy? , 2012, European Respiratory Journal.

[22]  S. Sahn,et al.  Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. , 2011, American journal of respiratory and critical care medicine.

[23]  G. Raghu.  Idiopathic pulmonary fibrosis: increased survival with "gastroesophageal reflux therapy": fact or fallacy? , 2011, American journal of respiratory and critical care medicine.

[24]  H. Collard,et al.  Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.

[25]  J. Egan,et al.  Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis , 2011, European Respiratory Journal.

[26]  M. Remy-Jardin,et al.  Exacerbations of idiopathic pulmonary fibrosis treated with corticosteroids and cyclophosphamide pulses , 2011, European Respiratory Journal.

[27]  A. Montgomery,et al.  Ambulatory oxygen in interstitial lung disease , 2011, European Respiratory Journal.

[28]  E. Bagiella,et al.  Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. , 2011, American journal of respiratory and critical care medicine.

[29]  I. Noth,et al.  Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic pulmonary fibrosis , 2011, European Respiratory Journal.

[30]  S. Sahn,et al.  Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials , 2011, The Lancet.

[31]  S. Sahn,et al.  Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. , 2011, American journal of respiratory and critical care medicine.

[32]  Takeshi Johkoh,et al.  American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .

[33]  H. Collard,et al.  Clinical course and prediction of survival in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.

[34]  F. Martinez,et al.  Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema , 2010, European Respiratory Journal.

[35]  N. Young.  Telomere biology and telomere diseases: implications for practice and research. , 2010, Hematology. American Society of Hematology. Education Program.

[36]  P. Brillet,et al.  Progression of idiopathic pulmonary fibrosis: lessons from asymmetrical disease , 2010, Thorax.

[37]  H. Collard,et al.  A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. , 2010, The New England journal of medicine.

[38]  Société française de cardiologie,et al.  [Recommendations for clinical practice. Obstructive sleep apnea hypopnea syndrome in adults]. , 2010, Revue des maladies respiratoires.

[39]  R. Kozu,et al.  Differences in Response to Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease , 2010, Respiration.

[40]  G. Raghu,et al.  Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. , 2010, American journal of respiratory and critical care medicine.

[41]  Peter F. Crossno,et al.  Identification of early interstitial lung disease in an individual with genetic variations in ABCA3 and SFTPC. , 2010, Chest.

[42]  H. Collard,et al.  Does chronic microaspiration cause idiopathic pulmonary fibrosis? , 2010, The American journal of medicine.

[43]  D. Fairclough,et al.  Pirfenidone in idiopathic pulmonary fibrosis , 2010, European Respiratory Journal.

[44]  G. Raghu,et al.  Pirfenidone in idiopathic pulmonary fibrosis , 2009, European Respiratory Journal.

[45]  Y. Castier,et al.  Survival After Bilateral Versus Single-Lung Transplantation for Idiopathic Pulmonary Fibrosis , 2009, Annals of Internal Medicine.

[46]  I. D. Johnston,et al.  Cryptogenic fibrosing alveolitis and lung cancer: the BTS study , 2009, Thorax.

[47]  A. Nicholson,et al.  Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis , 2009, European Respiratory Journal.

[48]  H. Collard,et al.  Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. , 2009, Chest.

[49]  M. Fujita,et al.  Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis. , 2009, Respiratory medicine.

[50]  M. Humbert,et al.  Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome , 2009, European Respiratory Journal.

[51]  S. Sahn,et al.  Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial , 2009, The Lancet.

[52]  T. Suarez,et al.  Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. , 2009, Chest.

[53]  K. Chida,et al.  Cumulative incidence of and predictive factors for lung cancer in IPF , 2009, Respirology.

[54]  L. Cecchini,et al.  Mechanical Ventilation in Patients with End-Stage Idiopathic Pulmonary Fibrosis , 2009, Respiration.

[55]  N. Kohno,et al.  Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. , 2009, American journal of respiratory and critical care medicine.

[56]  J. Moran,et al.  Outcomes of patients admitted to the intensive care unit with idiopathic pulmonary fibrosis. , 2009, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.

[57]  H. Collard,et al.  Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. , 2009, Chest.

[58]  D. Hansell,et al.  The effect of diffuse pulmonary fibrosis on the reliability of CT signs of pulmonary hypertension. , 2008, Radiology.

[59]  G. Raghu,et al.  Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. , 2008, American journal of respiratory and critical care medicine.

[60]  S. Mallick.  Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit. , 2008, Respiratory medicine.

[61]  V. Cottin,et al.  ANCA-associated lung fibrosis: analysis of 17 patients. , 2008, Respiratory medicine.

[62]  S. Nathan,et al.  Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. , 2008, Respiratory medicine.

[63]  M. Horton,et al.  Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis , 2008, Thorax.

[64]  A. Mehta,et al.  Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease. , 2008, Respiratory medicine.

[65]  Y. Kondoh,et al.  Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis , 2008, Respirology.

[66]  K. Swanson,et al.  Doppler echocardiography-right heart catheterization relationships in patients with idiopathic pulmonary fibrosis and suspected pulmonary hypertension. , 2008, Medical science monitor : international medical journal of experimental and clinical research.

[67]  G. Paone,et al.  Colchicine, cyclophosphamide and prednisone in the treatment of mild-moderate idiopathic pulmonary fibrosis: comparison of three currently available therapeutic regimens. , 2008, European review for medical and pharmacological sciences.

[68]  S. Nathan,et al.  Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis. , 2008, Chest.

[69]  A. Holland,et al.  Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease , 2008, Thorax.

[70]  S. Nathan,et al.  Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant , 2007, European Respiratory Journal.

[71]  W. Travis,et al.  Early interstitial lung disease in familial pulmonary fibrosis. , 2007, American journal of respiratory and critical care medicine.

[72]  M. Uder,et al.  Progression of Fibrosis in Usual Interstitial Pneumonia: Serial Evaluation of the Native Lung after Single Lung Transplantation , 2007, Respiration.

[73]  R. Burgess,et al.  Sleep-Related Breathing Disorders in Patients with Idiopathic Pulmonary Fibrosis , 2007, Lung.

[74]  A. Nicholson,et al.  Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. , 2007, American journal of respiratory and critical care medicine.

[75]  J. Golden,et al.  Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation. , 2007, The Journal of thoracic and cardiovascular surgery.

[76]  P. Lansdorp,et al.  Telomerase mutations in families with idiopathic pulmonary fibrosis. , 2007, The New England journal of medicine.

[77]  H. Collard,et al.  Sildenafil improves walk distance in idiopathic pulmonary fibrosis. , 2007, Chest.

[78]  V. Cottin.  Interstitial lung disease: are we missing formes frustes of connective tissue disease? , 2006, European Respiratory Journal.

[79]  A. Nicholson,et al.  Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis , 2006, European Respiratory Journal.

[80]  R. Hubbard,et al.  Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK , 2006, Thorax.

[81]  B. Madden,et al.  A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. , 2006, Vascular pharmacology.

[82]  J. Behr,et al.  Brain natriuretic peptide is a prognostic parameter in chronic lung disease. , 2006, American journal of respiratory and critical care medicine.

[83]  S. Nathan,et al.  Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. , 2006, Chest.

[84]  A. Rubin,et al.  Survival in idiopathic pulmonary fibrosis-cytotoxic agents compared to corticosteroids. , 2006, Respiratory medicine.

[85]  D. Sugarbaker,et al.  Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. , 2006, The Journal of thoracic and cardiovascular surgery.

[86]  A. Nicholson,et al.  Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features , 2006, European Respiratory Journal.

[87]  G. Raghu,et al.  High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis , 2006, European Respiratory Journal.

[88]  V. Cottin,et al.  Combined pulmonary fibrosis and emphysema: an experimental and clinically relevant phenotype. , 2005, American journal of respiratory and critical care medicine.

[89]  H Page McAdams,et al.  Clinical and pathologic features of familial interstitial pneumonia. , 2005, American journal of respiratory and critical care medicine.

[90]  Katsutoshi Nakayama,et al.  Anticoagulant therapy for idiopathic pulmonary fibrosis. , 2005, Chest.

[91]  A. Malhotra,et al.  Lung volume and continuous positive airway pressure requirements in obstructive sleep apnea. , 2005, American journal of respiratory and critical care medicine.

[92]  T. Hartman,et al.  Familial idiopathic pulmonary fibrosis: clinical features and outcome. , 2005, Chest.

[93]  M. Vassallo,et al.  Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis , 2005, Palliative medicine.

[94]  P. Pellikka,et al.  Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. , 2004, Chest.

[95]  Douglas Curran-Everett,et al.  Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. , 2004, Chest.

[96]  F. Al-Hameed,et al.  Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. , 2004, Canadian respiratory journal.

[97]  G. Raghu,et al.  A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. , 2004, The New England journal of medicine.

[98]  R. Newton,et al.  A study of the cough reflex in idiopathic pulmonary fibrosis. , 2003, American journal of respiratory and critical care medicine.

[99]  Y. Castier,et al.  Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. , 2003, The Journal of thoracic and cardiovascular surgery.

[100]  M. Molina-Molina,et al.  Características clínicas y pronóstico de los pacientes con fibrosis pulmonar que ingresan en cuidados intensivos por insuficiencia respiratoria. Análisis de 20 casos , 2003 .

[101]  M. Sutton,et al.  Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. , 2003, American journal of respiratory and critical care medicine.

[102]  W. Seeger,et al.  Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial , 2002, The Lancet.

[103]  B. Afessa,et al.  Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit. , 2002, American journal of respiratory and critical care medicine.

[104]  M. Wahidi,et al.  Progression of idiopathic pulmonary fibrosis in native lungs after single lung transplantation. , 2002, Chest.

[105]  Jonathan Haines,et al.  Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. , 2002, American journal of respiratory and critical care medicine.

[106]  T. Laitinen,et al.  Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland , 2002, Thorax.

[107]  Paul J. Friedman,et al.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors , 2002, American journal of respiratory and critical care medicine.

[108]  P. Jolliet,et al.  Outcome of mechanical ventilation for acute respiratory failure in patients with pulmonary fibrosis , 2001, Intensive Care Medicine.

[109]  J. Tooze,et al.  Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. , 2001, American journal of respiratory and critical care medicine.

[110]  H. Mal,et al.  Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure. , 2001, Chest.

[111]  C. Guérin,et al.  Outcome of patients with idiopathic pulmonary fibrosis admitted to the ICU for respiratory failure. , 2001, Chest.

[112]  R. Hubbard,et al.  A survey of nocturnal hypoxaemia and health related quality of life in patients with cryptogenic fibrosing alveolitis , 2001, Thorax.

[113]  F. Askin,et al.  A mutation in the surfactant protein C gene associated with familial interstitial lung disease. , 2001, The New England journal of medicine.

[114]  D. Schroeder,et al.  Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival. , 2000, American journal of respiratory and critical care medicine.

[115]  G. Laurent,et al.  Adult familial cryptogenic fibrosing alveolitis in the United Kingdom , 2000, Thorax.

[116]  M. Kitaichi,et al.  Hospital-based historical cohort study of 234 histologically proven Japanese patients with IPF. , 1999, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[117]  D. Castell,et al.  Updated Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux Disease , 1999, The American Journal of Gastroenterology.

[118]  Stefano Nava,et al.  Lung and chest wall mechanics in ventilated patients with end stage idiopathic pulmonary fibrosis , 1999, Thorax.

[119]  G. Raghu,et al.  Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. , 1998, American journal of respiratory and critical care medicine.

[120]  F. Martinez,et al.  International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[121]  S. Swensen,et al.  Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. , 1998, American journal of respiratory and critical care medicine.

[122]  M A Schork,et al.  Idiopathic pulmonary fibrosis: predicting response to therapy and survival. , 1998, American journal of respiratory and critical care medicine.

[123]  R. G. Parrish,et al.  Pulmonary fibrosis deaths in the United States, 1979-1991. An analysis of multiple-cause mortality data. , 1996, American journal of respiratory and critical care medicine.

[124]  D. Morrison,et al.  Increased exercise capacity in hypoxemic patients after long-term oxygen therapy. , 1992, Chest.

[125]  G. Raghu,et al.  Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. , 1991, The American review of respiratory disease.

[126]  I. D. Johnston,et al.  What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. , 1990, BMJ.

[127]  J. Darbyshire,et al.  Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. , 1989, Thorax.

[128]  F. Sériès,et al.  Increasing the functional residual capacity may reverse obstructive sleep apnea. , 1988, Sleep.

[129]  R. Crystal,et al.  Familial idiopathic pulmonary fibrosis. Evidence of lung inflammation in unaffected family members. , 1986, The New England journal of medicine.

[130]  M. Kamboh,et al.  Genetic studies in familial fibrosing alveolitis. Possible linkage with immunoglobulin allotypes (Gm). , 1986, Chest.

[131]  T. De,et al.  Parenteral nutrition before gastrointestinal surgery. , 1982 .

[132]  Cotes Je,et al.  LONG TERM DOMICILIARY OXYGEN THERAPY IN CHRONIC HYPOXIC COR PULMONALE COMPLICATING CHRONIC BRONCHITIS AND EMPHYSEMA Report of the Medical Research Council Working Party , 1981, The Lancet.

[133]  B. Burrows,et al.  Cryptogenic fibrosing alveolitis: clinical features and their influence on survival , 1980, Thorax.

[134]  J. Allen,et al.  Diffuse interstitial pneumonitis. Clinicopathologic correlations in 20 patients treated with prednisone/azathioprine. , 1978, The American journal of medicine.

[135]  D. Lynch,et al.  BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.

[136]  K. Kubo,et al.  Noninvasive ventilation in acute exacerbation of idiopathic pulmonary fibrosis. , 2010, Internal medicine.

[137]  G. Snell,et al.  Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years. , 2009, Transplantation proceedings.

[138]  G. Raghu,et al.  BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. , 2008, American journal of respiratory and critical care medicine.

[139]  Ouyang Shun-lin.  Applied values of hypopneic indices in the treatment for obstructive sleep apnea-hypopnea syndrome in adults , 2007 .

[140]  M. Aydoğdu,et al.  [Assessment of sleep with polysomnography in patients with interstitial lung disease]. , 2006, Tuberkuloz ve toraks.

[141]  M. Santos,et al.  [Outcomes and clinical characteristics of patients with pulmonary fibrosis and respiratory failure admitted to an intensive care unit. A study of 20 cases]. , 2003, Medicina clinica.

[142]  R. Hubbard,et al.  Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. , 2000, American journal of respiratory and critical care medicine.